Two hands of different skin tones giving a high-five against a plain background.

Contact

CONNECT WITH US AND HELP US SAVE LIVES

Want to partner with us, or are curious about what we do?

Reach out and we'll be in touch in no time!

GET IN TOUCH

Have a question? We're here to help!

Thank you for your submission!

Oops! Something went wrong while submitting the form.

info@signal26bio.com

email is copied!

For any inquiries or questions, reach out.

+41 (0)12 345 6789

phone number is copied!

Want to chat? Give us a call.

StartLab, Rte de la Corniche 5A, 1066 Epalinges, Switzerland

location is copied!

You can find us here.

WANT TO KNOW MORE?

FAQs

Find answers to commonly asked questions about Signal26

What is Psoriasis

Psoriasis is a chronic autoimmune condition that affects the skin, causing red, scaly patches to appear. It is caused by an overactive immune system.

How does IL-26 work?

IL-26 is a cytokine that plays a role in the inflammatory response. It is believed to contribute to the pathology of Psoriasis and other autoimmune diseases.

What is the novel anti-IL-26 antibody?

The novel anti-IL-26 antibody is a biologic treatment developed by Signal 26 Biotherapeutics. It has been shown to effectively block the aberrant function of IL-26 in the autoinflammation process.

What are the target diseases?

The target diseases for the novel anti-IL-26 antibody include Psoriasis, Inflammatory Bowel Disease, and Rheumatoid Arthritis.

When will the clinical trials begin?

Signal26 Biotherapeutics is committed to advancing the novel anti-IL-26 antibody to clinical trials as swiftly as possible to evaluate its safety and efficacy. We plan to begin the first in human trials in 2026.

Eager to learn more?

Explore the future with us

Learn more about Signal26, our research, and our roadmap through the links below.